In 2013, WHO released new treatment recommendations that expand the number of people eligible for treatment. The groups newly eligible for treatment include the following: all HIV-infected pregnant women, HIV-infected adults with hepatitis B infection and severe liver disease, serodiscordant couples, adults with CD4þ T-cell ...

Efavirenz is one of the most widely used nonnucleoside reverse transcriptase inhibitors (NNRTIs) in first-line antiretroviral therapy (ART) and is recommended as a preferred option in adult treatment guidelines. However, data from primate studies and some human case reports have raised concern regarding a association ...

Antiretroviral treatment (ART) has converted a highly fatal HIV infection into a chronic condition that requires lifelong care. Within the past decade, worldwide access to ART has improved significantly, with almost 10 million people receiving ART by the end of 2012. In addition to its ...

Global efforts to scale up antiretroviral therapy (ART) between 2002 and 2012 averted an estimated 4.2 million deaths in low-income and middle-income countries. The United Nations endorsed the importance of this impact and agreed to scale up ART to 15 million people by 2015. In ...

Aims of the new WHO HTS guidelines Addressing the testing gap Getting testing out intocommunities Supporting better linkage Better focus and appropriate targeting Improving quality to prevent misdiagnosis

The optimal timing for initiating antiretroviral therapy (ART) in individuals infected with HIV-1 has not yet been resolved. The US Department of Health and Human Services and the International Antiviral Society – USA recommend starting ART as close to diagnosis as possible. France and Brazil ...

The 2013 ‘Consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection’, released in July 2013, are the latest and most comprehensive of a series of important guidelines on antiretroviral therapy (ART) over the last decade from the World Health ...

With this update of the consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, WHO, for the first time, recommends that all people living with HIV be provided with antiretroviral therapy (ART). This will bring us one step closer to ...

The second edition of the World Health Organization (WHO) consolidated guidelines on the use of antiretrovirals (ARVs) updates the 2013 edition following an extensive review of evidence undertaken in 2015. Experience from country programmes, consultations with communities and modelling of potential impact have informed the ...

These consolidated guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. They are structured along the continuum of HIV testing, care and ...

Objective: The objective was to evaluate community and healthcare worker (HCW) values and preferences on key topics to inform the development of the 2013 WHO consolidated guidelines for antiretroviral therapy in low and middle income countries. Design: Cross-sectional e-survey and e-forum discussion; focus group discussions (FGDs) Methods: ...

In June 2013, the WHO released consolidated guidelines on the use of antiretrovirals (ARVs) . The launch of these new guidelines is another milestone in the global endeavor toward universal access to antiretroviral treatment (ART) using the public health approach, pursuing the dual advantage of ...

By the end of 2012, the number of people receiving antiretroviral treatment (ART) in low and middle-income countries reached 9.7 million, including 7.2 million in sub-Saharan Africa. The bad news is that these figures represent only 65% of the global target of 15 million people ...

Objective: To determine the status of key national policies on the use of antiretroviral therapy (ART) at the time of the launch of the 2013 WHO consolidated guidelines as well as to track early progress towards adoption of these recommendations following dissemination. Design: Descriptive analysis of ...

Revisions to the April 8, 2015, version of the guidelines are largely based on findings from two large, randomized controlled trials that addressed the optimal time to initiate antiretroviral therapy (ART)—START (Strategic Timing of Antiretroviral Therapy) and TEMPRANO. Both studies demonstrated approximately a 50% reduction ...